Alamar Capital Management LLC Acquires Shares of 13,605 DexCom, Inc. $DXCM

Alamar Capital Management LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,605 shares of the medical device company’s stock, valued at approximately $854,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Reflection Asset Management bought a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Ascentis Independent Advisors purchased a new position in DexCom in the 1st quarter valued at approximately $25,000. CVA Family Office LLC grew its stake in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares in the last quarter. MCF Advisors LLC bought a new stake in DexCom during the 4th quarter valued at $32,000. Finally, ORG Partners LLC raised its holdings in DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM opened at $71.43 on Thursday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The stock has a fifty day moving average of $72.01 and a 200 day moving average of $68.89. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm has a market capitalization of $27.56 billion, a price-to-earnings ratio of 30.53, a P/E/G ratio of 1.23 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the company earned $0.32 EPS. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. On average, research analysts expect that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DXCM shares. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Bank of America dropped their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Sanford C. Bernstein set a $77.00 target price on DexCom in a research note on Friday, May 1st. Benchmark reaffirmed a “buy” rating on shares of DexCom in a report on Tuesday, June 23rd. Finally, Deutsche Bank Aktiengesellschaft started coverage on DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $85.36.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares in the company, valued at $27,538,704. This represents a 6.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,750 shares of company stock valued at $5,163,241 in the last ninety days. Insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.